Entera Bio reports Q2 2026 results, cites FDA alignment on EB613 Phase 3 designAug 7Quarterly updateEntera Bio Ltd.
Lilly wins two label supplements: orforglipron tablet and teriparatide solutionAug 4Weekly roundup, 2 itemsEli Lillyorforglipron
Sign inSign in